Amphastar Pharmaceuticals Inc [AMPH] stock is trading at $45.32, up 6.79%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMPH shares have gain 2.86% over the last week, with a monthly amount glided 14.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] stock has seen the most recent analyst activity on March 05, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $60. Previously, BofA Securities started tracking the stock with Neutral rating on November 17, 2023, and set its price target to $63. CapitalOne initiated its recommendation with a Overweight and recommended $44 as its price target on July 29, 2022. Piper Sandler upgraded its rating to Overweight for this stock on January 07, 2022, and upped its price target to $28. In a note dated January 08, 2021, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $21.
Amphastar Pharmaceuticals Inc [AMPH] stock has fluctuated between $36.56 and $65.92 over the past year. Currently, Wall Street analysts expect the stock to reach $66 within the next 12 months. Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] shares were valued at $45.32 at the most recent close of the market. An investor can expect a potential return of 45.63% based on the average AMPH price forecast.
Analyzing the AMPH fundamentals
Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] reported sales of 712.89M for the trailing twelve months, which represents a growth of 25.17%. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.25 and Total Capital is 0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.64 points at the first support level, and at 41.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.17, and for the 2nd resistance point, it is at 47.03.
Ratios To Look Out For
For context, Amphastar Pharmaceuticals Inc’s Current Ratio is 3.52. In addition, the Quick Ratio stands at 2.63 and the Cash Ratio stands at 1.39. Considering the valuation of this stock, the price to sales ratio is 3.09, the price to book ratio is 3.11 and price to earnings (TTM) ratio is 14.44.
Transactions by insiders
Recent insider trading involved PRINS RICHARD K, Director, that happened on Aug 12 ’24 when 17101.0 shares were sold. Director, Richard Prins completed a deal on Aug 12 ’24 to buy 17101.0 shares. Meanwhile, CFO, EVP & TREASURER PETERS WILLIAM J sold 10282.0 shares on Jul 31 ’24.
